The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -1.9 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Halozyme Therapeutics's Beneish M-Score or its related term are showing as below:
STU:RV7'
s Beneish M-Score Range Over the Past 10 Years
Min: -4.76 Med: -2.07 Max: 14.91
Current: -1.9
During the past 13 years, the highest Beneish M-Score of Halozyme Therapeutics was 14.91. The lowest was -4.76. And the median was -2.07.
Halozyme Therapeutics Beneish M-Score Related Terms
Halozyme Therapeutics Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RV7 vs KYMR, IBRX, PRAX: Beneish M-Score Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Halozyme Therapeutics for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0913
+
0.528 * 1.0083
+
0.404 * 1.514
+
0.892 * 1.2883
+
0.115 * 0.9608
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9903
+
4.679 * -0.001837
-
0.327 * 1.1397
=
-1.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(75.642 / (75.642 + 67.355))
/
(87.137 / (87.137 + 71.129))
=
0.528976
/
0.550573
=
0.9608
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(301.359 - -275.827
-
581.432)
/
2311.902
=
-0.001837
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Halozyme Therapeutics has a M-score of -1.98 suggests that the company is unlikely to be a manipulator.
Halozyme Therapeutics (STU:RV7) has a Beneish M-Score of -1.90 as of Jul. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Halozyme Therapeutics and its competitors. According to the industry distribution chart, Halozyme Therapeutics ranks #532 out of 825 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Halozyme Therapeutics' Beneish M-Score too high?
Halozyme Therapeutics' current Beneish M-Score is -1.90. Based on the distribution chart, Halozyme Therapeutics ranks #532 out of 825 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Beneish M-Score compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #532 out of 825 companies for Beneish M-Score. This places Halozyme Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Beneish M-Score is -1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (STU:RV7) is currently considered Modestly Undervalued. The stock's GF Value™ is €79.06, compared to a current price of €66.76 — trading 15.6% below its estimated fair value. The current Beneish M-Score is -1.90. Halozyme Therapeutics' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Halozyme Therapeutics (STU:RV7), the current Beneish M-Score is -1.90 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (STU:RV7) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of €66.76 is trading 15.6% below its estimated GF Value™ of €79.06.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:RV7:
Beneish M-Score: -1.90
GF Value™: €79.06 vs. price of €66.76 (15.6% below fair value)
No single metric tells the full story. See the STU:RV7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
73GF Score
Get the complete analysis for STU:RV7
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RV7 has been successfully added to your 
